This is a phase I, interventional, single arm, open label, treatment study to evaluate the
safety and tolerability of BCMA-CD19 cCAR T cells in patients with relapsed and/or refractory
Systemic lupus erythematous (SLE) is a chronic diffuse connective tissue disease with
unexplained etiology that can involve multiple systems in the body. SLE is considered as an
incurable disease and traditional SLE treatment aims at long-term remission. Glucocorticoids
combined with immunosuppressive agents are still the main treatment strategies. Recently,
biological agents targeting abnormal immune cells, such as rituximab and belimumab, which
deplete B cells have also achieved some success in the treatment of SLE. However, these
agents cannot permanently reverse the production of abnormal antibodies as they are unable to
eliminate pathogenic long-lived plasma cells. The BCMA-CD19 CAR T-cells are designed to
deplete antibody-producing 'root", B cells and plasma cells.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.